Loading
A phase 2 trial of Poziotinib in Breast cancer, run by Spectrum Pharmaceuticals, Inc, recorded as terminated on the registry.
A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib is a phase 2 interventional study registered as NCT03744715 by Spectrum Pharmaceuticals, Inc, with 7 participants recorded, started 2018-10-11 and due to reach its primary completion in 2023-03-03. Interventions recorded: Poziotinib. Conditions recorded: NSCLC, Breast Cancer.
Linked to the drug Poziotinib because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
7 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2026-07-28), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs)primary | Poziotinib 6 mg | 1 | 1 participants | - | - | link |
| Poziotinib 8 mg | 1 | 1 participants | ||||
| Poziotinib 12 mg | 1 | 1 participants | ||||
| Poziotinib 14 mg | 1 | 1 participants | ||||
| Poziotinib 16 mg | 2 | 2 participants | ||||
| Poziotinib 24 mg | 1 | 1 participants |
Shares Poziotinib, Spectrum Pharmaceuticals, Breast cancer (all types) and the tag pipeline.
Shares Poziotinib, Spectrum Pharmaceuticals, Breast cancer (all types) and the tag pipeline.
Shares Spectrum Pharmaceuticals and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.